Stay updated with breaking news from Early Access Programs. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Biophytis / Key word(s): Miscellaneous Biophytis announces positive final results of the phase 2-3 COVA study with Sarconeos (BIO1...
Biophytis / Key word(s): Miscellaneous Biophytis announces positive final results of the phase 2-3 COVA study with Sarconeos (BIO101) in severe COVID-19 02-Feb-2023 / 08:00 CET/CEST Biophytis announces positive final results of the phase 2-3 COVA study with Sarconeos (BIO101) in severe COVID-19 C...
Prescription product net revenue of approximately $3.1 million in Q3 2022 increased 8.2% over Q2 2022 and increased approximately 412% over prescription product net revenue in Q3 2021Core initiatives:OnTarget
Special Note Regarding Forward-Looking Statements Certain statements in this Report contain forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of... | November 14, 2022
Company completed a public offering for aggregate gross proceeds of $16.8 millionMajority of clinical sites now open in clinical study to evaluate QRX003...